Dynavax Drops Tolamba After Phase IIb Flop
This article was originally published in The Pink Sheet Daily
Fate of firm’s cat and peanut allergy programs hangs in balance.
You may also be interested in...
Phase III subject diagnosed with Wegener’s granulomatosis, a rare blood vessel inflammation.
BLA asking approval of one-month, two-dose vaccine regimen anticipated in second half of 2008.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.